Charles Schwab Investment Management Inc Sc Pharmaceuticals Inc. Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Sc Pharmaceuticals Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 75,890 shares of SCPH stock, worth $257,267. This represents 0.0% of its overall portfolio holdings.

Number of Shares

75,890

Previous 79,202 4.18%

Holding current value

$257,267

Previous $344,000 0.58%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$4.12 - $5.51 $13,645 - $18,249	-3,312 Reduced 4.18%	75,890 $346,000
Q2 2024 Aug 12, 2024	BUY	$3.51 - $5.21 $23,320 - $34,615	6,644 Added 9.16%	79,202 $344,000
Q1 2024 May 08, 2024	SELL	$4.86 - $6.39 $23,585 - $31,010	-4,853 Reduced 6.27%	72,558 $364,000
Q4 2023 Feb 06, 2024	SELL	$4.7 - $6.63 $850 - $1,200	-181 Reduced 0.23%	77,411 $485,000
Q3 2023 Nov 08, 2023	BUY	$7.0 - $9.82 $26,369 - $36,991	3,767 Added 5.1%	77,592 $552,000
Q2 2023 Aug 09, 2023	BUY	$8.94 - $11.74 $659,995 - $866,705	73,825 New	73,825 $752,000
Q2 2021 Aug 16, 2021	SELL	$5.19 - $7.38 $74,720 - $106,249	-14,397 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$5.65 - $7.66 $41,872 - $56,768	-7,411 Reduced 33.98%	14,397 $96,000
Q3 2020 Nov 13, 2020	BUY	$7.12 - $8.86 $20,284 - $25,242	2,849 Added 15.03%	21,808 $163,000
Q2 2020 Aug 14, 2020	BUY	$7.01 - $10.96 $132,902 - $207,790	18,959 New	18,959 $140,000
Q2 2019 Aug 09, 2019	SELL	$2.48 - $3.76 $33,232 - $50,384	-13,400 Closed	0 $0
Q1 2018 May 07, 2018	BUY	$11.62 - $17.32 $155,708 - $232,088	13,400 New	13,400 $167,000

Others Institutions Holding SCPH

# of Institutions

Shares Held

37.1M

Call Options Held

110K

Put Options Held

12.1K

View Full List

About scPharmaceuticals Inc.

Ticker SCPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,402,100
Market Cap $92.9M
Description
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product p...

More about SCPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Sc Pharmaceuticals Inc. Transaction History